| Nome: | Descrição: | Tamanho: | Formato: | |
|---|---|---|---|---|
| 1.52 MB | Adobe PDF |
Orientador(es)
Resumo(s)
In late 2019, COVID-19 emerged in Wuhan, China. Currently, it is an ongoing global health threat stressing the need for therapeutic compounds. Linking the virus life cycle and its interaction with cell receptors and internal cellular machinery is key to developing therapies based on the control of infectivity and inflammation. In this framework, we evaluate the combination of cannabidiol (CBD), as an anti-inflammatory molecule, and terpenes, by their anti-microbiological properties, in reducing SARS-CoV-2 infectivity. Our group settled six formulations combining CBD and terpenes purified from Cannabis sativa L, Origanum vulgare, and Thymus mastichina. The formulations were analyzed by HPLC and GC-MS and evaluated for virucide and antiviral potential by in vitro studies in alveolar basal epithelial, colon, kidney, and keratinocyte human cell lines.
Descrição
Palavras-chave
CBD - cannabidiol Endocannabinoid system (ECS) SARS-CoV-2 Therapeutics Terpenes Formulations Essential oil (EO)
Contexto Educativo
Citação
Santos, S., Barata, P., Charmier, A., Lehmann, I., Rodrigues, S., Melosini, M. M., Pais, P. J., Sousa, A. P., Teixeira, C., Santos, I., Rocha, A. C., Baylina, P., & Fernandes, R. (2022). Cannabidiol and terpene formulation reducing SARS-CoV-2 infectivity tackling a therapeutic strategy. Frontiers in Immunology, 13, 1–12. https://doi.org/10.3389/fimmu.2022.841459
Editora
Frontiers